Press Release discussing the financial results for the second quarter and half year ended as on September 30, 2026 is attached.

A fi C U T fi a S® ACUTAAS CHEMICALS LIMITED (Formerly known as Ami Organics Limited) CIN No. : L24100GJ2007PLCO51093 You and us: chemistry’s apex October 27, 2026 To, To, The Listing Department, The Listing Department BSE LIMITED, National Stock Exchange of India Limited, Phiroze Jeejeebhoy Towers, Exchange Plaza, 5% Floor, Plot No. C-1, Dalal Street, Fort G-Block, Bandra Kurla Complex, Mumbai- 400 001 Mumbai -400051 Scrip Code: 543349 NSE Symbol: ACUTAAS Subject: Press Release pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, In accordance with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a Press Release discussing the financial results of second quarter and half year ended as on September 30, 2026. This Press Release will be available on the website of the Company www.acutaas.com. Kindly take the same on record. Yours faithfully, For, ACUTAAS CHEMICALS LIMITED Ekta Kumari Srivastava Company Secretary & Compliance Officer Encl: Press Release . +9175730 15366, +91 72279 77744 © Registered Office: Plot No. 440/4, 5 & 6, i info@acutaas.com Road No. 82/A, GIDC Sachin, # www.acutaas.com Dist. Surat - 394230, Gujarat, India PRESS RELEASE For Immediate dissemination Acutaas Chemicals Limited reports Q2 & H1 FY27 Results Q2 FY27 Revenue from Operation at ₹4,369mn, up 42.7% YoY Q2 FY27 PAT at ₹1,231mn, up 71.4% YoY; PAT Margins at 28.2% Surat, October 27, 2026: Acutaas Chemicals Limited (BSE: 543349, NSE: ACUTAAS), a leading global manufacturer of advance pharmaceutical intermediates and speciality chemicals, today announced financial results for the quarter and half year ended September 30, 2026. Consolidated Financial Results – Q2 & H1 FY27: Particulars (Rs. Mn) Q2FY27 Q2FY26 YoY Q1FY27 QoQ H1FY27 H1FY26 YoY Revenue from Operations 4,369 3,062 42.7% 3,297 32.5% 7,666 5,134 49.3% Gross Profit 2,715 1,707 59.0% 1,909 42.2% 4,624 2,811 64.5% Gross Margin 62.1% 55.8% 57.9% 60.3% 54.7% EBITDA 1,760 953 84.6% 1,131 55.6% 2,890 1,462 97.7% EBITDA Margin 40.3% 31.1% 34.3% 37.7% 28.5% PAT 1,231 719 71.4% 750 64.2% 1,981 1,159 71.0% PAT Margin 28.2% 23.5% 22.7% 25.8% 22.6% Commenting on results, Mr. Naresh Patel, Executive Chairman & Managing Director, Acutaas Chemicals Limited, said: “We delivered strong revenue of ₹4,369 million, representing 42.7% year-on-year growth. The performance was led by the continued momentum in our Pharmaceutical Intermediates business, which was offset by softer performance in the Specialty Chemicals segment. A significant milestone during the quarter was the inauguration of our South Korea manufacturing facility ahead of schedule. The facility is equipped to produce high-purity chemicals used in photoresists, semiconductor packaging materials, etching materials and other semiconductor applications, positioning us to capitalize on opportunities in the fast- growing semiconductor ecosystem. Improved revenue visibility and robust order pipeline gives me confidence to revise our FY27 revenue growth guidance upward from 25% to around 30%. We are also raising our EBITDA margin guidance to 38-40% range.” Key Results & Business Highlights (Q2 FY27 Consolidated): ✓ Revenue from operations for Q2FY27 grew by 42.7% YoY to Rs. 4,369 mn ✓ The gross margin for the quarter improved to 62.1% up 637 bps YoY ✓ EBITDA for the quarter came at Rs. 1,760 mn up 84.6% YoY PRESS RELEASE For Immediate dissemination ✓ EBITDA margin for the quarter was at 40.3% as compared to 31.1% in Q2FY26 ✓ PAT for the quarter was Rs. 1,231 mn up 71.4% as compared to PAT of Rs. 719 mn in Q2FY26 ✓ The PAT margin for the quarter was at 28.2% up 472 bps YoY ABOUT ACUTAAS CHEMICALS LIMITED: Acutaas Chemicals Limited is a speciality chemicals manufacturer serving a wide range of industries, including pharmaceuticals, semiconductors, battery chemicals, personal care, agrochemicals, and fine chemicals. Our core strength lies in the research-driven development and manufacturing of advanced pharmaceutical intermediates used in both regulated and generic APIs, as well as intermediates for New Chemical Entities (NCEs). We are also expanding our portfolio to include high-value speciality chemicals for emerging technologies such as battery materials, semiconductor, and next-generation electronic applications. CAUTIONARY STATEMENT: This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Acutaas Chemicals Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent. For details, please contact: Investor Relations at Acutaas Chemicals Registered Office Limited Plot no. 440/4, 5 & 6, Road No. 82/A, Senior Manager – Investor Relations GIDC Sachin, Surat- 394230 Mr. Rahul Thakur CIN: L24100GJ2007PLC051093 Rahul.thakur@acutaas.com ISIN: INE00FF01025 NSE Code: ACUTAAS BSE CODE: 543349 Website: www.acutaas.com